Cholestatic liver diseases:An era of emerging therapies
|
摘要
Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease.Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid(UDCA),the current standard treatment for cholestatic liver disease.Important novel treatment targets now also include nuclear receptors involved in bile acid(BA)homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5".Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA.In this review,we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease.Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid(UDCA),the current standard treatment for cholestatic liver disease.Important novel treatment targets now also include nuclear receptors involved in bile acid(BA)homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5".Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA.In this review,we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
Recently the field of cholestasis has expanded enormously reflecting an improved understanding of the molecular mechanisms underlying bile secretion and its perturbation in chronic cholestatic disease.Novel anti-cholestatic therapeutic options have been developed for patients not favorably responding to ursodeoxycholic acid(UDCA),the current standard treatment for cholestatic liver disease.Important novel treatment targets now also include nuclear receptors involved in bile acid(BA)homoeostasis like farnesoid X receptor and G proteincoupled receptors e.g., the G-protein-coupled BA receptor "transmembrane G coupled receptor 5".Fibroblast growth factor-19 and enterohepatic BA transporters also deserve attention as additional drug targets as does the potential treatment agent norUDCA.In this review,we discuss recent and future promising therapeutic agents and their potential molecular mechanisms in cholestatic liver disorders.
引文
1 Trauner M,Meier PJ,Boyer JL.Molecular pathogenesis of cholestasis.N Engl J Med 1998;339:1217-1227[PMID:9780343 DOI:10.1056/NEJM199810223391707]
2 Beuers U,Trauner M,Jansen P,Poupon R.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond.J Hepatol 2015;62:S25-S37[PMID:25920087 DOI:10.1016/j.jhep.2015.02.023]
3 Russell DW.The enzymes,regulation,and genetics of bile acid synthesis.Annu Rev Biochem 2003;72:137-174[PMID:12543708 DOI:10.1146/annurev.biochem.72.121801.161712]
4 Strazzabosco M,Fabris L,Spirli C.Pathophysiology of cholangiopathies.J Clin Gastroenterol 2005;39:S90-S102[PMID:15758666]
5 Trauner M,Boyer JL.Bile salt transporters:molecular characterization,function,and regulation.Physiol Rev 2003;83:633-671[PMID:12663868 DOI:10.1152/physrev.00027.2002]
6 Ananthanarayanan M,Balasubramanian N,Makishima M,Mangelsdorf DJ,Suchy FJ.Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.J Biol Chem 2001;276:28857-28865[PMID:11387316 DOI:10.1074/jbc.M011610200]
7 Kast HR,Goodwin B,Tarr PT,Jones SA,Anisfeld AM,Stoltz CM,Tontonoz P,Kliewer S,Willson TM,Edwards PA.Regulation of multidrug resistance-associated protein 2(ABCC2)by the nuclear receptors pregnane X receptor,farnesoid X-activated receptor,and constitutive androstane receptor.J Biol Chem2002;277:2908-2915[PMID:11706036 DOI:10.1074/jbc.M109326200]
8 Zollner G,Marschall HU,Wagner M,Trauner M.Role of nuclear receptors in the adaptive response to bile acids and cholestasis:pathogenetic and therapeutic considerations.Mol Pharm 2006;3:231-251[PMID:16749856 DOI:10.1021/mp060010s]
9 Corso G,Dello Russo A,Gelzo M.Liver and the defects of cholesterol and bile acids biosynthesis:Rare disorders many diagnostic pitfalls.World J Gastroenterol 2017;23:5257-5265[PMID:28839426 DOI:10.3748/wjg.v23.i29.5257]
10 Dilger K,Hohenester S,Winkler-Budenhofer U,Bastiaansen BA,Schaap FG,Rust C,Beuers U.Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.J Hepatol 2012;57:133-140[PMID:22414767 DOI:10.1016/j.jhep.2012.02.014]
11 Benz C,Angermüller S,Otto G,Sauer P,Stremmel W,Stiehl A.Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes.Eur J Clin Invest 2000;30:203-209[PMID:10691996 DOI:10.1046/j.1365-2362.2000.00615.x]
12 Miura T,Ouchida R,Yoshikawa N,Okamoto K,Makino Y,Nakamura T,Morimoto C,Makino I,Tanaka H.Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid.J Biol Chem 2001;276:47371-47378[PMID:11577102 DOI:10.1074/jbc.M107098200]
13 Poupon R,Chrétien Y,Poupon RE,Ballet F,Calmus Y,Darnis F.Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?Lancet 1987;1:834-836[PMID:2882236]
14 Parés A,Caballería L,Rodés J,Bruguera M,Rodrigo L,García-Plaza A,Berenguer J,RodríguezMartínez D,Mercader J,Velicia R.Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis:results of a double-blind controlled multicentric trial.UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.J Hepatol 2000;32:561-566[PMID:10782903 DOI:10.1016/S0168-8278(00)80216-0]
15 Lammers WJ,Hirschfield GM,Corpechot C,Nevens F,Lindor KD,Janssen HL,Floreani A,Ponsioen CY,Mayo MJ,Invernizzi P,Battezzati PM,Parés A,Burroughs AK,Mason AL,Kowdley KV,Kumagi T,Harms MH,Trivedi PJ,Poupon R,Cheung A,Lleo A,Caballeria L,Hansen BE,van Buuren HR;Global PBC Study Group.Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.Gastroenterology 2015;149:1804-1812.e4[PMID:26261009 DOI:10.1053/j.gastro.2015.07.061]
16 Corpechot C,Carrat F,Bahr A,Chrétien Y,Poupon RE,Poupon R.The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.Gastroenterology 2005;128:297-303[PMID:15685541 DOI:10.1053/j.gastro.2004.11.009]
17 European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases.J Hepatol 2009;51:237-267[PMID:19501929 DOI:10.1016/j.jhep.2009.04.009]
18 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
19 Seol W,Choi HS,Moore DD.Isolation of proteins that interact specifically with the retinoid X receptor:two novel orphan receptors.Mol Endocrinol 1995;9:72-85[PMID:7760852 DOI:10.1210/mend.9.1.7760852]
20 Makishima M,Okamoto AY,Repa JJ,Tu H,Learned RM,Luk A,Hull MV,Lustig KD,Mangelsdorf DJ,Shan B.Identification of a nuclear receptor for bile acids.Science 1999;284:1362-1365[PMID:10334992 DOI:10.1126/science.284.5418.1362]
21 Wang H,Chen J,Hollister K,Sowers LC,Forman BM.Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.Mol Cell 1999;3:543-553[PMID:10360171 DOI:10.1016/S1097-2765(00)80348-2]
22 Halilbasic E,Baghdasaryan A,Trauner M.Nuclear receptors as drug targets in cholestatic liver diseases.Clin Liver Dis 2013;17:161-189[PMID:23540496 DOI:10.1016/j.cld.2012.12.001]
23 Zhu C,Fuchs CD,Halilbasic E,Trauner M.Bile acids in regulation of inflammation and immunity:friend or foe?Clin Exp Rheumatol 2016;34:25-31[PMID:27586800]
24 Verbeke L,Farre R,Verbinnen B,Covens K,Vanuytsel T,Verhaegen J,Komuta M,Roskams T,Chatterjee S,Annaert P,Vander Elst I,Windmolders P,Trebicka J,Nevens F,Laleman W.The FXRagonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.Am J Pathol 2015;185:409-419[PMID:25592258 DOI:10.1016/j.ajpath.2014.10.009]
25 Nevens F,Andreone P,Mazzella G,Strasser SI,Bowlus C,Invernizzi P,Drenth JP,Pockros PJ,Regula J,Beuers U,Trauner M,Jones DE,Floreani A,Hohenester S,Luketic V,Shiffman M,van Erpecum KJ,Vargas V,Vincent C,Hirschfield GM,Shah H,Hansen B,Lindor KD,Marschall HU,Kowdley KV,Hooshmand-Rad R,Marmon T,Sheeron S,Pencek R,MacConell L,Pruzanski M,Shapiro D;POISEStudy Group.A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.N Engl JMed 2016;375:631-643[PMID:27532829 DOI:10.1056/NEJMoa1509840]
26 Hirschfield GM,Mason A,Luketic V,Lindor K,Gordon SC,Mayo M,Kowdley KV,Vincent C,Bodhenheimer HC,Parés A,Trauner M,Marschall HU,Adorini L,Sciacca C,Beecher-Jones T,Castelloe E,B?hm O,Shapiro D.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.Gastroenterology 2015;148:751-61.e8[PMID:25500425DOI:10.1053/j.gastro.2014.12.005]
27 Larusso NF,Bowlus CL,Levy C,Vuppalanchi R,Floreani A,Andreone P,Srestha R,Trotter J,Goldberg D,Rushbrook S,Hirschfield GM,Van Biene V,Penceck R,Macconell L,David S.The AESOP Trial:ARandomized,Double-Blind,Placebo-Controlled,Phase 2 Study of Obeticholic Acid in Patients with Primary Sclerosing Cholangitis.Digest Liver Dis 2018;50:e67[DOI:10.1016/s1590-8658(18)30266-4]
28 Nicholes K,Guillet S,Tomlinson E,Hillan K,Wright B,Frantz GD,Pham TA,Dillard-Telm L,Tsai SP,Stephan JP,Stinson J,Stewart T,French DM.A mouse model of hepatocellular carcinoma:ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.Am J Pathol 2002;160:2295-2307[PMID:12057932 DOI:10.1016/S0002-9440(10)61177-7]
29 Zweers SJ,Booij KA,Komuta M,Roskams T,Gouma DJ,Jansen PL,Schaap FG.The human gallbladder secretes fibroblast growth factor 19 into bile:towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.Hepatology 2012;55:575-583[PMID:21953282 DOI:10.1002/hep.24702]
30 Myers RP,Djedjos C,Kirby B,Bilin A,Khan M,Gosink J,Song Q,Srihari R.A198 Pharmacodynamic Effects of the Oral,Non-steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers.JCanadian Assoc of Gastroenterology 2018;1:346[DOI:10.1093/jcag/gwy008.199]
31 Makishima M,Lu TT,Xie W,Whitfield GK,Domoto H,Evans RM,Haussler MR,Mangelsdorf DJ.Vitamin D receptor as an intestinal bile acid sensor.Science 2002;296:1313-1316[PMID:12016314DOI:10.1126/science.1070477]
32 Kir S,Beddow SA,Samuel VT,Miller P,Previs SF,Suino-Powell K,Xu HE,Shulman GI,Kliewer SA,Mangelsdorf DJ.FGF19 as a postprandial,insulin-independent activator of hepatic protein and glycogen synthesis.Science 2011;331:1621-1624[PMID:21436455 DOI:10.1126/science.1198363]
33 Zhou M,Learned RM,Rossi SJ,DePaoli AM,Tian H,Ling L.Engineered fibroblast growth factor 19reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.Hepatology 2016;63:914-929[PMID:26418580 DOI:10.1002/hep.28257]
34 Zhou M,Wang X,Phung V,Lindhout DA,Mondal K,Hsu JY,Yang H,Humphrey M,Ding X,Arora T,Learned RM,DePaoli AM,Tian H,Ling L.Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.Cancer Res 2014;74:3306-3316[PMID:24728076 DOI:10.1158/0008-5472.CAN-14-0208]
35 Mayo MJ,Wigg AJ,Leggett BA,Arnold H,Thompson AJ,Weltman M,Carey EJ,Muir AJ,Ling L,Rossi SJ,DePaoli AM.NGM282 for Treatment of Patients With Primary Biliary Cholangitis:AMulticenter,Randomized,Double-Blind,Placebo-Controlled Trial.Hepatol Commun 2018;2:1037-1050[PMID:30202819 DOI:10.1002/hep4.1209]
36 Maruyama T,Miyamoto Y,Nakamura T,Tamai Y,Okada H,Sugiyama E,Nakamura T,Itadani H,Tanaka K.Identification of membrane-type receptor for bile acids(M-BAR).Biochem Biophys Res Commun 2002;298:714-719[PMID:12419312 DOI:10.1016/S0006-291X(02)02550-0]
37 Maruyama T,Tanaka K,Suzuki J,Miyoshi H,Harada N,Nakamura T,Miyamoto Y,Kanatani A,Tamai Y.Targeted disruption of G protein-coupled bile acid receptor 1(Gpbar1/M-Bar)in mice.J Endocrinol2006;191:197-205[PMID:17065403 DOI:10.1677/joe.1.06546]
38 Keitel V,Cupisti K,Ullmer C,Knoefel WT,Kubitz R,H?ussinger D.The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders.Hepatology 2009;50:861-870[PMID:19582812 DOI:10.1002/hep.23032]
39 Wang YD,Chen WD,Yu D,Forman BM,Huang W.The G-protein-coupled bile acid receptor,Gpbar1(TGR5),negatively regulates hepatic inflammatory response through antagonizing nuclear factorκlightchain enhancer of activated B cells(NF-κB)in mice.Hepatology 2011;54:1421-1432[PMID:21735468DOI:10.1002/hep.24525]
40 Cipriani S,Mencarelli A,Chini MG,Distrutti E,Renga B,Bifulco G,Baldelli F,Donini A,Fiorucci S.The bile acid receptor GPBAR-1(TGR5)modulates integrity of intestinal barrier and immune response to experimental colitis.PLoS One 2011;6:e25637[PMID:22046243 DOI:10.1371/journal.pone.0025637]
41 Pellicciari R,Gioiello A,Macchiarulo A,Thomas C,Rosatelli E,Natalini B,Sardella R,Pruzanski M,Roda A,Pastorini E,Schoonjans K,Auwerx J.Discovery of 6alpha-ethyl-23(S)-methylcholic acid(S-EMCA,INT-777)as a potent and selective agonist for the TGR5 receptor,a novel target for diabesity.JMed Chem 2009;52:7958-7961[PMID:20014870 DOI:10.1021/jm901390p]
42 Lieu T,Jayaweera G,Zhao P,Poole DP,Jensen D,Grace M,McIntyre P,Bron R,Wilson YM,Krappitz M,Haerteis S,Korbmacher C,Steinhoff MS,Nassini R,Materazzi S,Geppetti P,Corvera CU,Bunnett NW.The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice.Gastroenterology2014;147:1417-1428[PMID:25194674 DOI:10.1053/j.gastro.2014.08.042]
43 Rizzo G,Passeri D,De Franco F,Ciaccioli G,Donadio L,Rizzo G,Orlandi S,Sadeghpour B,Wang XX,Jiang T,Levi M,Pruzanski M,Adorini L.Functional characterization of the semisynthetic bile acid derivative INT-767,a dual farnesoid X receptor and TGR5 agonist.Mol Pharmacol 2010;78:617-630[PMID:20631053 DOI:10.1124/mol.110.064501]
44 Baghdasaryan A,Claudel T,Gumhold J,Silbert D,Adorini L,Roda A,Vecchiotti S,Gonzalez FJ,Schoonjans K,Strazzabosco M,Fickert P,Trauner M.Dual farnesoid X receptor/TGR5 agonist INT-767reduces liver injury in the Mdr2-/-(Abcb4-/-)mouse cholangiopathy model by promoting biliary HCOoutput.Hepatology 2011;54:1303-1312[PMID:22006858 DOI:10.1002/hep.24537]
45 Duboc H,TachéY,Hofmann AF.The bile acid TGR5 membrane receptor:from basic research to clinical application.Dig Liver Dis 2014;46:302-312[PMID:24411485 DOI:10.1016/j.dld.2013.10.021]
46 Perides G,Laukkarinen JM,Vassileva G,Steer ML.Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1.Gastroenterology 2010;138:715-725[PMID:19900448 DOI:10.1053/j.gastro.2009.10.052]
47 Pawlak M,Lefebvre P,Staels B.Molecular mechanism of PPARαaction and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease.J Hepatol 2015;62:720-733[PMID:25450203 DOI:10.1016/j.jhep.2014.10.039]
48 Cao W,Tian W,Hong J,Li D,Tavares R,Noble L,Moss SF,Resnick MB.Expression of bile acid receptor TGR5 in gastric adenocarcinoma.Am J Physiol Gastrointest Liver Physiol 2013;304:G322-G327[PMID:23238937 DOI:10.1152/ajpgi.00263.2012]
49 Ghonem NS,Assis DN,Boyer JL.Fibrates and cholestasis.Hepatology 2015;62:635-643[PMID:25678132 DOI:10.1002/hep.27744]
50 Pawlak M,BaugéE,Bourguet W,De Bosscher K,Lalloyer F,Tailleux A,Lebherz C,Lefebvre P,Staels B.The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.Hepatology 2014;60:1593-1606[PMID:24995693 DOI:10.1002/hep.27297]
51 Cuperus FJ,Halilbasic E,Trauner M.Fibrate treatment for primary biliary cirrhosis.Curr Opin Gastroenterol 2014;30:279-286[PMID:24625898 DOI:10.1097/MOG.0000000000000056]
52 Zhang Y,Chen K,Dai W,Xia Y,Wang F,Shen M,Cheng P,Wang C,Yang J,Zhu R,Zhang H,Li J,Zheng Y,Wang J,Lu J,Zhou Y,Guo C.Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis:A meta-analysis.Hepatol Res 2015;45:48-58[PMID:24934524 DOI:10.1111/hepr.12373]
53 Hosonuma K,Sato K,Yamazaki Y,Yanagisawa M,Hashizume H,Horiguchi N,Kakizaki S,Kusano M,Yamada M.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.Am JGastroenterol 2015;110:423-431[PMID:25732417 DOI:10.1038/ajg.2015.20]
54 Cheung AC,Lapointe-Shaw L,Kowgier M,Meza-Cardona J,Hirschfield GM,Janssen HL,Feld JJ.Combined ursodeoxycholic acid(UDCA)and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.Aliment Pharmacol Ther 2016;43:283-293[PMID:26559762 DOI:10.1111/apt.13465]
55 Ratziu V,Harrison SA,Francque S,Bedossa P,Lehert P,Serfaty L,Romero-Gomez M,Boursier J,Abdelmalek M,Caldwell S,Drenth J,Anstee QM,Hum D,Hanf R,Roudot A,Megnien S,Staels B,Sanyal A;GOLDEN-505 Investigator Study Group.Elafibranor,an Agonist of the Peroxisome Proliferator-Activated Receptor-αand-δ,Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Gastroenterology 2016;150:1147-1159.e5[PMID:26874076 DOI:10.1053/j.gastro.2016.01.038]
56 Hofmann AF,Zakko SF,Lira M,Clerici C,Hagey LR,Lambert KK,Steinbach JH,Schteingart CD,Olinga P,Groothuis GM.Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.Hepatology 2005;42:1391-1398[PMID:16317695 DOI:10.1002/hep.20943]
57 Dumont M,Erlinger S,Uchman S.Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat:possible role of bicarbonate transport.Gastroenterology 1980;79:82-89[PMID:7380227 DOI:10.1016/0016-5085(80)90078-5]
58 Fickert P,Pollheimer MJ,Silbert D,Moustafa T,Halilbasic E,Krones E,Durchschein F,Thüringer A,Zollner G,Denk H,Trauner M.Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.J Hepatol 2013;58:1201-1208[PMID:23369794 DOI:10.1016/j.jhep.2013.01.026]
59 Trauner M,Fickert P,Hirschfield G,Reiter F,Altorjay I,Marschall HU,F?rkkil?M,Schramm C,Spengler U,Chapman R,Bergquist A,Schrumpf E,Nevens F,Halilbasic E,Greinwald R,Proels M,Manns MP.Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis:results of a phase II dose finding study.J Hepatol 2016;64:S208-S209[DOI:10.1016/S0168-8278(16)00171-9]
60 Baghdasaryan A,Fuchs CD,?sterreicher CH,Lemberger UJ,Halilbasic E,P?hlman I,Graffner H,Krones E,Fickert P,Wahlstr?m A,St?hlman M,Paumgartner G,Marschall HU,Trauner M.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol 2016;64:674-681[PMID:26529078 DOI:10.1016/j.jhep.2015.10.024]
61 Graffner H,Gillberg PG,Rikner L,Marschall HU.The ileal bile acid transporter inhibitor A4250decreases serum bile acids by interrupting the enterohepatic circulation.Aliment Pharmacol Ther 2016;43:303-310[PMID:26527417 DOI:10.1111/apt.13457]
62 Mayo MJ,Pockros P,Jones D,Bowlus C,Levy C,Patanwala I,Bacort B,Luketic V,Vuppalanchi R,Medendorp S,Dorenbaum A,Kennedy C,Novak P,Raychaudhuri A,Goyal S,Abi-Saab W,Hirschfield GM.Clarity;a phase II,randomized,double-blind,placebo-controlled study of LUM001,a novel apical sodium-dependent bile acid transporter inhibitor,in the treatment of primary biliary cirrhosis associated with itching.J Hepatol 2016;64:S197[DOI:10.1016/S0168-8278(16)00146-X]
63 Hegade VS,Kendrick SF,Dobbins RL,Miller SR,Thompson D,Richards D,Storey J,Dukes GE,Corrigan M,Oude Elferink RP,Beuers U,Hirschfield GM,Jones DE.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:a double-blind,randomised,placebocontrolled,crossover,phase 2a study.Lancet 2017;389:1114-1123[PMID:28187915 DOI:10.1016/S0140-6736(17)30319-7]
2 Beuers U,Trauner M,Jansen P,Poupon R.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond.J Hepatol 2015;62:S25-S37[PMID:25920087 DOI:10.1016/j.jhep.2015.02.023]
3 Russell DW.The enzymes,regulation,and genetics of bile acid synthesis.Annu Rev Biochem 2003;72:137-174[PMID:12543708 DOI:10.1146/annurev.biochem.72.121801.161712]
4 Strazzabosco M,Fabris L,Spirli C.Pathophysiology of cholangiopathies.J Clin Gastroenterol 2005;39:S90-S102[PMID:15758666]
5 Trauner M,Boyer JL.Bile salt transporters:molecular characterization,function,and regulation.Physiol Rev 2003;83:633-671[PMID:12663868 DOI:10.1152/physrev.00027.2002]
6 Ananthanarayanan M,Balasubramanian N,Makishima M,Mangelsdorf DJ,Suchy FJ.Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.J Biol Chem 2001;276:28857-28865[PMID:11387316 DOI:10.1074/jbc.M011610200]
7 Kast HR,Goodwin B,Tarr PT,Jones SA,Anisfeld AM,Stoltz CM,Tontonoz P,Kliewer S,Willson TM,Edwards PA.Regulation of multidrug resistance-associated protein 2(ABCC2)by the nuclear receptors pregnane X receptor,farnesoid X-activated receptor,and constitutive androstane receptor.J Biol Chem2002;277:2908-2915[PMID:11706036 DOI:10.1074/jbc.M109326200]
8 Zollner G,Marschall HU,Wagner M,Trauner M.Role of nuclear receptors in the adaptive response to bile acids and cholestasis:pathogenetic and therapeutic considerations.Mol Pharm 2006;3:231-251[PMID:16749856 DOI:10.1021/mp060010s]
9 Corso G,Dello Russo A,Gelzo M.Liver and the defects of cholesterol and bile acids biosynthesis:Rare disorders many diagnostic pitfalls.World J Gastroenterol 2017;23:5257-5265[PMID:28839426 DOI:10.3748/wjg.v23.i29.5257]
10 Dilger K,Hohenester S,Winkler-Budenhofer U,Bastiaansen BA,Schaap FG,Rust C,Beuers U.Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.J Hepatol 2012;57:133-140[PMID:22414767 DOI:10.1016/j.jhep.2012.02.014]
11 Benz C,Angermüller S,Otto G,Sauer P,Stremmel W,Stiehl A.Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes.Eur J Clin Invest 2000;30:203-209[PMID:10691996 DOI:10.1046/j.1365-2362.2000.00615.x]
12 Miura T,Ouchida R,Yoshikawa N,Okamoto K,Makino Y,Nakamura T,Morimoto C,Makino I,Tanaka H.Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid.J Biol Chem 2001;276:47371-47378[PMID:11577102 DOI:10.1074/jbc.M107098200]
13 Poupon R,Chrétien Y,Poupon RE,Ballet F,Calmus Y,Darnis F.Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?Lancet 1987;1:834-836[PMID:2882236]
14 Parés A,Caballería L,Rodés J,Bruguera M,Rodrigo L,García-Plaza A,Berenguer J,RodríguezMartínez D,Mercader J,Velicia R.Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis:results of a double-blind controlled multicentric trial.UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.J Hepatol 2000;32:561-566[PMID:10782903 DOI:10.1016/S0168-8278(00)80216-0]
15 Lammers WJ,Hirschfield GM,Corpechot C,Nevens F,Lindor KD,Janssen HL,Floreani A,Ponsioen CY,Mayo MJ,Invernizzi P,Battezzati PM,Parés A,Burroughs AK,Mason AL,Kowdley KV,Kumagi T,Harms MH,Trivedi PJ,Poupon R,Cheung A,Lleo A,Caballeria L,Hansen BE,van Buuren HR;Global PBC Study Group.Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.Gastroenterology 2015;149:1804-1812.e4[PMID:26261009 DOI:10.1053/j.gastro.2015.07.061]
16 Corpechot C,Carrat F,Bahr A,Chrétien Y,Poupon RE,Poupon R.The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.Gastroenterology 2005;128:297-303[PMID:15685541 DOI:10.1053/j.gastro.2004.11.009]
17 European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases.J Hepatol 2009;51:237-267[PMID:19501929 DOI:10.1016/j.jhep.2009.04.009]
18 Lindor KD,Kowdley KV,Luketic VA,Harrison ME,McCashland T,Befeler AS,Harnois D,Jorgensen R,Petz J,Keach J,Mooney J,Sargeant C,Braaten J,Bernard T,King D,Miceli E,Schmoll J,Hoskin T,Thapa P,Enders F.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.Hepatology 2009;50:808-814[PMID:19585548 DOI:10.1002/hep.23082]
19 Seol W,Choi HS,Moore DD.Isolation of proteins that interact specifically with the retinoid X receptor:two novel orphan receptors.Mol Endocrinol 1995;9:72-85[PMID:7760852 DOI:10.1210/mend.9.1.7760852]
20 Makishima M,Okamoto AY,Repa JJ,Tu H,Learned RM,Luk A,Hull MV,Lustig KD,Mangelsdorf DJ,Shan B.Identification of a nuclear receptor for bile acids.Science 1999;284:1362-1365[PMID:10334992 DOI:10.1126/science.284.5418.1362]
21 Wang H,Chen J,Hollister K,Sowers LC,Forman BM.Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.Mol Cell 1999;3:543-553[PMID:10360171 DOI:10.1016/S1097-2765(00)80348-2]
22 Halilbasic E,Baghdasaryan A,Trauner M.Nuclear receptors as drug targets in cholestatic liver diseases.Clin Liver Dis 2013;17:161-189[PMID:23540496 DOI:10.1016/j.cld.2012.12.001]
23 Zhu C,Fuchs CD,Halilbasic E,Trauner M.Bile acids in regulation of inflammation and immunity:friend or foe?Clin Exp Rheumatol 2016;34:25-31[PMID:27586800]
24 Verbeke L,Farre R,Verbinnen B,Covens K,Vanuytsel T,Verhaegen J,Komuta M,Roskams T,Chatterjee S,Annaert P,Vander Elst I,Windmolders P,Trebicka J,Nevens F,Laleman W.The FXRagonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.Am J Pathol 2015;185:409-419[PMID:25592258 DOI:10.1016/j.ajpath.2014.10.009]
25 Nevens F,Andreone P,Mazzella G,Strasser SI,Bowlus C,Invernizzi P,Drenth JP,Pockros PJ,Regula J,Beuers U,Trauner M,Jones DE,Floreani A,Hohenester S,Luketic V,Shiffman M,van Erpecum KJ,Vargas V,Vincent C,Hirschfield GM,Shah H,Hansen B,Lindor KD,Marschall HU,Kowdley KV,Hooshmand-Rad R,Marmon T,Sheeron S,Pencek R,MacConell L,Pruzanski M,Shapiro D;POISEStudy Group.A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.N Engl JMed 2016;375:631-643[PMID:27532829 DOI:10.1056/NEJMoa1509840]
26 Hirschfield GM,Mason A,Luketic V,Lindor K,Gordon SC,Mayo M,Kowdley KV,Vincent C,Bodhenheimer HC,Parés A,Trauner M,Marschall HU,Adorini L,Sciacca C,Beecher-Jones T,Castelloe E,B?hm O,Shapiro D.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.Gastroenterology 2015;148:751-61.e8[PMID:25500425DOI:10.1053/j.gastro.2014.12.005]
27 Larusso NF,Bowlus CL,Levy C,Vuppalanchi R,Floreani A,Andreone P,Srestha R,Trotter J,Goldberg D,Rushbrook S,Hirschfield GM,Van Biene V,Penceck R,Macconell L,David S.The AESOP Trial:ARandomized,Double-Blind,Placebo-Controlled,Phase 2 Study of Obeticholic Acid in Patients with Primary Sclerosing Cholangitis.Digest Liver Dis 2018;50:e67[DOI:10.1016/s1590-8658(18)30266-4]
28 Nicholes K,Guillet S,Tomlinson E,Hillan K,Wright B,Frantz GD,Pham TA,Dillard-Telm L,Tsai SP,Stephan JP,Stinson J,Stewart T,French DM.A mouse model of hepatocellular carcinoma:ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.Am J Pathol 2002;160:2295-2307[PMID:12057932 DOI:10.1016/S0002-9440(10)61177-7]
29 Zweers SJ,Booij KA,Komuta M,Roskams T,Gouma DJ,Jansen PL,Schaap FG.The human gallbladder secretes fibroblast growth factor 19 into bile:towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.Hepatology 2012;55:575-583[PMID:21953282 DOI:10.1002/hep.24702]
30 Myers RP,Djedjos C,Kirby B,Bilin A,Khan M,Gosink J,Song Q,Srihari R.A198 Pharmacodynamic Effects of the Oral,Non-steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers.JCanadian Assoc of Gastroenterology 2018;1:346[DOI:10.1093/jcag/gwy008.199]
31 Makishima M,Lu TT,Xie W,Whitfield GK,Domoto H,Evans RM,Haussler MR,Mangelsdorf DJ.Vitamin D receptor as an intestinal bile acid sensor.Science 2002;296:1313-1316[PMID:12016314DOI:10.1126/science.1070477]
32 Kir S,Beddow SA,Samuel VT,Miller P,Previs SF,Suino-Powell K,Xu HE,Shulman GI,Kliewer SA,Mangelsdorf DJ.FGF19 as a postprandial,insulin-independent activator of hepatic protein and glycogen synthesis.Science 2011;331:1621-1624[PMID:21436455 DOI:10.1126/science.1198363]
33 Zhou M,Learned RM,Rossi SJ,DePaoli AM,Tian H,Ling L.Engineered fibroblast growth factor 19reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.Hepatology 2016;63:914-929[PMID:26418580 DOI:10.1002/hep.28257]
34 Zhou M,Wang X,Phung V,Lindhout DA,Mondal K,Hsu JY,Yang H,Humphrey M,Ding X,Arora T,Learned RM,DePaoli AM,Tian H,Ling L.Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.Cancer Res 2014;74:3306-3316[PMID:24728076 DOI:10.1158/0008-5472.CAN-14-0208]
35 Mayo MJ,Wigg AJ,Leggett BA,Arnold H,Thompson AJ,Weltman M,Carey EJ,Muir AJ,Ling L,Rossi SJ,DePaoli AM.NGM282 for Treatment of Patients With Primary Biliary Cholangitis:AMulticenter,Randomized,Double-Blind,Placebo-Controlled Trial.Hepatol Commun 2018;2:1037-1050[PMID:30202819 DOI:10.1002/hep4.1209]
36 Maruyama T,Miyamoto Y,Nakamura T,Tamai Y,Okada H,Sugiyama E,Nakamura T,Itadani H,Tanaka K.Identification of membrane-type receptor for bile acids(M-BAR).Biochem Biophys Res Commun 2002;298:714-719[PMID:12419312 DOI:10.1016/S0006-291X(02)02550-0]
37 Maruyama T,Tanaka K,Suzuki J,Miyoshi H,Harada N,Nakamura T,Miyamoto Y,Kanatani A,Tamai Y.Targeted disruption of G protein-coupled bile acid receptor 1(Gpbar1/M-Bar)in mice.J Endocrinol2006;191:197-205[PMID:17065403 DOI:10.1677/joe.1.06546]
38 Keitel V,Cupisti K,Ullmer C,Knoefel WT,Kubitz R,H?ussinger D.The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders.Hepatology 2009;50:861-870[PMID:19582812 DOI:10.1002/hep.23032]
39 Wang YD,Chen WD,Yu D,Forman BM,Huang W.The G-protein-coupled bile acid receptor,Gpbar1(TGR5),negatively regulates hepatic inflammatory response through antagonizing nuclear factorκlightchain enhancer of activated B cells(NF-κB)in mice.Hepatology 2011;54:1421-1432[PMID:21735468DOI:10.1002/hep.24525]
40 Cipriani S,Mencarelli A,Chini MG,Distrutti E,Renga B,Bifulco G,Baldelli F,Donini A,Fiorucci S.The bile acid receptor GPBAR-1(TGR5)modulates integrity of intestinal barrier and immune response to experimental colitis.PLoS One 2011;6:e25637[PMID:22046243 DOI:10.1371/journal.pone.0025637]
41 Pellicciari R,Gioiello A,Macchiarulo A,Thomas C,Rosatelli E,Natalini B,Sardella R,Pruzanski M,Roda A,Pastorini E,Schoonjans K,Auwerx J.Discovery of 6alpha-ethyl-23(S)-methylcholic acid(S-EMCA,INT-777)as a potent and selective agonist for the TGR5 receptor,a novel target for diabesity.JMed Chem 2009;52:7958-7961[PMID:20014870 DOI:10.1021/jm901390p]
42 Lieu T,Jayaweera G,Zhao P,Poole DP,Jensen D,Grace M,McIntyre P,Bron R,Wilson YM,Krappitz M,Haerteis S,Korbmacher C,Steinhoff MS,Nassini R,Materazzi S,Geppetti P,Corvera CU,Bunnett NW.The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice.Gastroenterology2014;147:1417-1428[PMID:25194674 DOI:10.1053/j.gastro.2014.08.042]
43 Rizzo G,Passeri D,De Franco F,Ciaccioli G,Donadio L,Rizzo G,Orlandi S,Sadeghpour B,Wang XX,Jiang T,Levi M,Pruzanski M,Adorini L.Functional characterization of the semisynthetic bile acid derivative INT-767,a dual farnesoid X receptor and TGR5 agonist.Mol Pharmacol 2010;78:617-630[PMID:20631053 DOI:10.1124/mol.110.064501]
44 Baghdasaryan A,Claudel T,Gumhold J,Silbert D,Adorini L,Roda A,Vecchiotti S,Gonzalez FJ,Schoonjans K,Strazzabosco M,Fickert P,Trauner M.Dual farnesoid X receptor/TGR5 agonist INT-767reduces liver injury in the Mdr2-/-(Abcb4-/-)mouse cholangiopathy model by promoting biliary HCOoutput.Hepatology 2011;54:1303-1312[PMID:22006858 DOI:10.1002/hep.24537]
45 Duboc H,TachéY,Hofmann AF.The bile acid TGR5 membrane receptor:from basic research to clinical application.Dig Liver Dis 2014;46:302-312[PMID:24411485 DOI:10.1016/j.dld.2013.10.021]
46 Perides G,Laukkarinen JM,Vassileva G,Steer ML.Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1.Gastroenterology 2010;138:715-725[PMID:19900448 DOI:10.1053/j.gastro.2009.10.052]
47 Pawlak M,Lefebvre P,Staels B.Molecular mechanism of PPARαaction and its impact on lipid metabolism,inflammation and fibrosis in non-alcoholic fatty liver disease.J Hepatol 2015;62:720-733[PMID:25450203 DOI:10.1016/j.jhep.2014.10.039]
48 Cao W,Tian W,Hong J,Li D,Tavares R,Noble L,Moss SF,Resnick MB.Expression of bile acid receptor TGR5 in gastric adenocarcinoma.Am J Physiol Gastrointest Liver Physiol 2013;304:G322-G327[PMID:23238937 DOI:10.1152/ajpgi.00263.2012]
49 Ghonem NS,Assis DN,Boyer JL.Fibrates and cholestasis.Hepatology 2015;62:635-643[PMID:25678132 DOI:10.1002/hep.27744]
50 Pawlak M,BaugéE,Bourguet W,De Bosscher K,Lalloyer F,Tailleux A,Lebherz C,Lefebvre P,Staels B.The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.Hepatology 2014;60:1593-1606[PMID:24995693 DOI:10.1002/hep.27297]
51 Cuperus FJ,Halilbasic E,Trauner M.Fibrate treatment for primary biliary cirrhosis.Curr Opin Gastroenterol 2014;30:279-286[PMID:24625898 DOI:10.1097/MOG.0000000000000056]
52 Zhang Y,Chen K,Dai W,Xia Y,Wang F,Shen M,Cheng P,Wang C,Yang J,Zhu R,Zhang H,Li J,Zheng Y,Wang J,Lu J,Zhou Y,Guo C.Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis:A meta-analysis.Hepatol Res 2015;45:48-58[PMID:24934524 DOI:10.1111/hepr.12373]
53 Hosonuma K,Sato K,Yamazaki Y,Yanagisawa M,Hashizume H,Horiguchi N,Kakizaki S,Kusano M,Yamada M.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.Am JGastroenterol 2015;110:423-431[PMID:25732417 DOI:10.1038/ajg.2015.20]
54 Cheung AC,Lapointe-Shaw L,Kowgier M,Meza-Cardona J,Hirschfield GM,Janssen HL,Feld JJ.Combined ursodeoxycholic acid(UDCA)and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.Aliment Pharmacol Ther 2016;43:283-293[PMID:26559762 DOI:10.1111/apt.13465]
55 Ratziu V,Harrison SA,Francque S,Bedossa P,Lehert P,Serfaty L,Romero-Gomez M,Boursier J,Abdelmalek M,Caldwell S,Drenth J,Anstee QM,Hum D,Hanf R,Roudot A,Megnien S,Staels B,Sanyal A;GOLDEN-505 Investigator Study Group.Elafibranor,an Agonist of the Peroxisome Proliferator-Activated Receptor-αand-δ,Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Gastroenterology 2016;150:1147-1159.e5[PMID:26874076 DOI:10.1053/j.gastro.2016.01.038]
56 Hofmann AF,Zakko SF,Lira M,Clerici C,Hagey LR,Lambert KK,Steinbach JH,Schteingart CD,Olinga P,Groothuis GM.Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.Hepatology 2005;42:1391-1398[PMID:16317695 DOI:10.1002/hep.20943]
57 Dumont M,Erlinger S,Uchman S.Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat:possible role of bicarbonate transport.Gastroenterology 1980;79:82-89[PMID:7380227 DOI:10.1016/0016-5085(80)90078-5]
58 Fickert P,Pollheimer MJ,Silbert D,Moustafa T,Halilbasic E,Krones E,Durchschein F,Thüringer A,Zollner G,Denk H,Trauner M.Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.J Hepatol 2013;58:1201-1208[PMID:23369794 DOI:10.1016/j.jhep.2013.01.026]
59 Trauner M,Fickert P,Hirschfield G,Reiter F,Altorjay I,Marschall HU,F?rkkil?M,Schramm C,Spengler U,Chapman R,Bergquist A,Schrumpf E,Nevens F,Halilbasic E,Greinwald R,Proels M,Manns MP.Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis:results of a phase II dose finding study.J Hepatol 2016;64:S208-S209[DOI:10.1016/S0168-8278(16)00171-9]
60 Baghdasaryan A,Fuchs CD,?sterreicher CH,Lemberger UJ,Halilbasic E,P?hlman I,Graffner H,Krones E,Fickert P,Wahlstr?m A,St?hlman M,Paumgartner G,Marschall HU,Trauner M.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol 2016;64:674-681[PMID:26529078 DOI:10.1016/j.jhep.2015.10.024]
61 Graffner H,Gillberg PG,Rikner L,Marschall HU.The ileal bile acid transporter inhibitor A4250decreases serum bile acids by interrupting the enterohepatic circulation.Aliment Pharmacol Ther 2016;43:303-310[PMID:26527417 DOI:10.1111/apt.13457]
62 Mayo MJ,Pockros P,Jones D,Bowlus C,Levy C,Patanwala I,Bacort B,Luketic V,Vuppalanchi R,Medendorp S,Dorenbaum A,Kennedy C,Novak P,Raychaudhuri A,Goyal S,Abi-Saab W,Hirschfield GM.Clarity;a phase II,randomized,double-blind,placebo-controlled study of LUM001,a novel apical sodium-dependent bile acid transporter inhibitor,in the treatment of primary biliary cirrhosis associated with itching.J Hepatol 2016;64:S197[DOI:10.1016/S0168-8278(16)00146-X]
63 Hegade VS,Kendrick SF,Dobbins RL,Miller SR,Thompson D,Richards D,Storey J,Dukes GE,Corrigan M,Oude Elferink RP,Beuers U,Hirschfield GM,Jones DE.Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:a double-blind,randomised,placebocontrolled,crossover,phase 2a study.Lancet 2017;389:1114-1123[PMID:28187915 DOI:10.1016/S0140-6736(17)30319-7]